The economic efficiency of timely diagnosis and early treatment of type 2 diabetes
https://doi.org/10.14341/probl20075367-11
Abstract
Туре 2 diabetes (T2D) is frequently detected too late just after development of complications requiring expensive treatment. The costs of drugs used for the treatment of diabetic complications are much greater than the funds allocated for diabetes management. The purpose of the study was to assess the impact of timely diagnosis and early initiated treatment of T2D on the total costs of the treatment. Direct and indirect costs of the treatment of the disease and its complications, using the Atakarov model with 5% annual allowance, were estimated. It was determined that with well-timed diagnosis of T2D), the total costs per patient cold be reduced by 1736 Litas or about 503 Eros (1 Euro = 3.452S Litas) over 5 years and over 10 years it would be saved even 1712 Euros. Not only indirect costs would be reduced. A total of 700 Euros would be saved per patient over 5 years and 2045 Euros over years. With the improved diagnosis of T2D and the well-timed diagnosis in at least 50% of cases of diabetes mellitus could save 10.05 million Euros over 5 years and even 34.23 million Euros over 10 years. The timely diagnosis of the disease and its proper management would prolong the life of a patient with T2D by 2.67 months over 10 years. That of T2D saves the costs of its treatment and care and can prolong the patient's life.
About the Authors
A. NorkusKaunas Medical University
Lithuania
R. Ostrauskas
Kaunas Medical University
Lithuania
R. Shukaite
Kaunas Medical University
Lithuania
References
1. Clarke P., Gray A., Legood R., Briggs A., Holman R. // Diabet. Med. - 2003. - Vol. 20. - P. 442-450.
2. Cowie С. С, Rust К. F., Byrd-Holt D. D. et al. // Diabetes Care. - 2006. - Vol. 29. - P. 1263-1268.
3. Deckert Т., Crenfell A. // Textbook of Diabetes. - Oxford. 1991.-P. 651-656.
4. Drummon M. F., Sculpher С W, Torrance G. W. et al. // Methods for the Economic Evaluation of Health Care Programmes. - 3-rd Ed. - Oxford, 2005. - P. 6-396.
5. For Confirmation of Recommendations for Pharmacological Economic Analysis of Drugs. The Edict of Minister of Health, 20-th January 2003. N. V-26 // Valstybes Zinios. - 2003. - N 13-532.
6. Gerstein H. С // Int. J. Clin. Pract. - 2001. - Vol. 117. -Suppl. - P. 8-12.
7. Harris M. I., Klein R., Welbom T. A., Kniuman M. W. // Diabetes Care. - 1992. - Vol. 15. - P. 815-819.
8. Hillier T.A., Pedula K. L. // Diabetes Care. - 2001. -Vol. 24. - P. 1522-1527.
9. Home P. // Curr. Med. Res. Opin. - 2005. - Vol. 21. -P. 989-998.
10. Jonsson B. // Diabetologia. - 2002. - Vol. 45. - P. S5-S12.
11. Lavigne J. E., Phelps С E., Mushlin A., Lednar W. M. // Pharmacoeconomics. - 2003. - Vol. 21. - P. 1123-1134.
12. Liebl A., Neiss A., Spannheimer A. et al. // Exp. Clin. Endocrinol. Diabet. - 2002. - Vol. 110. - P. 10-16.
13. Lipp A. J. // Public Hlth. - 2002. - Vol. 24. - P. 242.
14. Lucioni C, Garancini M. P., Massi-Benedetti M. et al. //Treat. Endocrinol. - 2003. - Vol. 2. - P. 121-133.
15. Norkus A., Domarkiene S., Sulcaite R. et al. // Lietuvos Endokrinol. - 2002. - Vol. 10. P. 60-66.
16. Rathmann W., Gianl G. // Diabetes Care. - 2004. - Vol. 27. -P. 2568-2569.
17. Spijkerman A. M., Dekker J. M., Nijpcls G. et al. // Diabetes Care. - 2003. - Vol. 26. - P. 2604-2608.
18. Stratton I. M., Adler A. I., Neil H. A. W et al. // Br. Med. J. -2000. - Vol. 321. - P. 405-412.
19. Williams R. // Diabetologia. - 2002. - Vol. 45. - P. S13-S17.
20. Wolford J. K., Vozarova de Courten B. // Treat. Endocrinol. - 2004. - Vol. 3. - P. 257-267.
Review
For citations:
Norkus A., Ostrauskas R., Shukaite R. The economic efficiency of timely diagnosis and early treatment of type 2 diabetes. Problems of Endocrinology. 2007;53(6):7-11. (In Russ.) https://doi.org/10.14341/probl20075367-11
Views:
854
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
